Published in J Infect Dis on April 01, 1998
Candida albicans secreted aspartyl proteinases in virulence and pathogenesis. Microbiol Mol Biol Rev (2003) 4.07
Immunopathogenesis of oropharyngeal candidiasis in human immunodeficiency virus infection. Clin Microbiol Rev (2004) 1.48
Oropharyngeal Candida colonization and human immunodeficiency virus type 1 infection. J Infect Dis (2000) 0.98
Impact of N-chlorotaurine on viability and production of secreted aspartyl proteinases of Candida spp. Antimicrob Agents Chemother (2002) 0.97
High aspartyl proteinase production and vaginitis in human immunodeficiency virus-infected women. J Clin Microbiol (1999) 0.85
Interaction of 5-hydroxytryptamine (serotonin) against Aspergillus spp. in vitro. Int J Antimicrob Agents (2007) 0.84
Human immunodeficiency virus type 1 Tat binds to Candida albicans, inducing hyphae but augmenting phagocytosis in vitro. Immunology (2001) 0.77
Interaction of serotonin with Candida albicans selectively attenuates fungal virulence in vitro. Int J Antimicrob Agents (2005) 0.77
HIV aspartyl protease inhibitors as promising compounds against Candida albicans André Luis Souza dos Santos. World J Biol Chem (2010) 0.77
Lack of ritonavir antifungal effect in vitro. Antimicrob Agents Chemother (1999) 0.76
Candida albicans delays HIV-1 replication in macrophages. PLoS One (2013) 0.75
Determinants of symptomatic vulvovaginal candidiasis among human immunodeficiency virus type 1 infected women in rural KwaZulu-Natal, South Africa. Infect Dis Obstet Gynecol (2014) 0.75
Neopterin as a marker for activated cell-mediated immunity: application in HIV infection. Immunol Today (1988) 3.13
Enhancement of sheep red blood cell human lymphocyte rosette formation by the sulfhydryl compound 2-amino ethylisothiouronium bromide. Clin Immunol Immunopathol (1975) 3.11
In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis. J Antimicrob Chemother (1998) 2.32
Candida albicans and Candida stellatoidea, in contrast to other Candida species, bind iC3b and C3d but not C3b. Infect Immun (1985) 2.25
Third component of complement (C3): structural properties in relation to functions. Proc Natl Acad Sci U S A (1975) 2.21
Growth control of activated, synchronized murine B cells by the C3d fragment of human complement. Nature (1985) 1.98
Strain-specific differences in the amount of Shiga toxin released from enterohemorrhagic Escherichia coli O157 following exposure to subinhibitory concentrations of antimicrobial agents. Eur J Clin Microbiol Infect Dis (1998) 1.77
C3bi-binding protein on Candida albicans: temperature-dependent expression and relationship to human complement receptor type 3. Infect Immun (1989) 1.76
Human immunodeficiency virus type 1 activates the classical pathway of complement by direct C1 binding through specific sites in the transmembrane glycoprotein gp41. J Exp Med (1991) 1.71
Qualitative and quantitative assessment of C3-receptor reactivities on lymphoid and phagocytic cells. J Immunol (1981) 1.57
Distribution of human endogenous retrovirus HERV-K genomes in humans and different primates. Hum Genet (1995) 1.52
[Vancomycin resistant enterococci in Austria]. Wien Klin Wochenschr (1997) 1.51
Studies of in vitro activities of voriconazole and itraconazole against Aspergillus hyphae using viability staining. Antimicrob Agents Chemother (2001) 1.50
Recombinant versus plasma-derived hepatitis B vaccine: comparison of immunogenicity in medical students. Vaccine (1992) 1.47
Acquisition of host cell-surface-derived molecules by HIV-1. AIDS (1996) 1.46
Molecular epidemiology of Klebsiella pneumoniae producing SHV-5 beta- lactamase: parallel outbreaks due to multiple plasmid transfer. J Clin Microbiol (1996) 1.45
Cytokine-induced generation of multinucleated giant cells in vitro requires interferon-gamma and expression of LFA-1. Eur J Immunol (1990) 1.44
Localization of the complement-component-C3b-binding site and the cofactor activity for factor I in the 38kDa tryptic fragment of factor H. Biochem J (1984) 1.44
Heterogeneity in the complement-dependent bacteriolysis within the species of Borrelia burgdorferi. Med Microbiol Immunol (1997) 1.44
Human macrophages degrade tryptophan upon induction by interferon-gamma. Life Sci (1987) 1.42
Antifungal properties of selective serotonin reuptake inhibitors against Aspergillus species in vitro. J Antimicrob Chemother (2001) 1.42
Reducing HIV transmission by seronegative blood. Lancet (1992) 1.41
The C-terminus of factor H: monoclonal antibodies inhibit heparin binding and identify epitopes common to factor H and factor H-related proteins. Biochem J (1998) 1.40
A new kind of orphan drug? Nature (1992) 1.38
Demonstration of binding sites for IgG Fc and the third complement component (C3) on isolated hepatocytes. J Immunol (1976) 1.36
Urinary tract infection caused by nontyphoidal Salmonella: report of 30 cases. Urol Int (1992) 1.33
Enzyme-linked immunosorbent assay for detection of T-2 toxin. Hoppe Seylers Z Physiol Chem (1982) 1.33
Streptococcal inhibitor of complement (SIC) inhibits the membrane attack complex by preventing uptake of C567 onto cell membranes. Immunology (2001) 1.31
Simultaneous infection with two drug-susceptible Mycobacterium tuberculosis strains in an immunocompetent host. J Clin Microbiol (1999) 1.29
Antifungal activity against Candida species of the selective serotonin-reuptake inhibitor, sertraline. Clin Infect Dis (2001) 1.29
HIV-1 gp41 contains two sites for interaction with several proteins on the helper T-lymphoid cell line, H9. AIDS (1992) 1.29
The yeast Candida albicans binds complement regulators factor H and FHL-1. Infect Immun (2002) 1.28
Screening for Aspergillus spp. using polymerase chain reaction of whole blood samples from patients with haematological malignancies. Br J Haematol (2001) 1.27
In vitro activity of fosfomycin in combination with various antistaphylococcal substances. J Antimicrob Chemother (2001) 1.24
Structural and functional analysis of the complement component factor H with the use of different enzymes and monoclonal antibodies to factor H. Biochem J (1985) 1.24
Efficient destruction of human immunodeficiency virus in human serum by inhibiting the protective action of complement factor H and decay accelerating factor (DAF, CD55). J Exp Med (1996) 1.23
Comparative study of five different techniques for epidemiological typing of Escherichia coli O157. Diagn Microbiol Infect Dis (1998) 1.22
Aspergillus terreus infections in haematological malignancies: molecular epidemiology suggests association with in-hospital plants. J Hosp Infect (2000) 1.21
Evaluation of C3 receptors on lymphoid cells with different complement sources. J Immunol (1974) 1.19
Role of complement in HIV infection. Annu Rev Immunol (1997) 1.18
Regulation of the expression of ICAM-1 on human monocytes and monocytic tumor cell lines. J Immunol (1992) 1.17
Essential role of surface-bound chemoattractant in leukocyte migration. Nature (1977) 1.15
Increased endogenous interferon-gamma and neopterin correlate with increased degradation of tryptophan in human immunodeficiency virus type 1 infection. Immunol Lett (1991) 1.14
Interferon-gamma concentrations are increased in sera from individuals infected with human immunodeficiency virus type 1. J Acquir Immune Defic Syndr (1989) 1.14
Neopterin modulates toxicity mediated by reactive oxygen and chloride species. FEBS Lett (1993) 1.14
Analysis of bypass activation of C3 by endotoxic LPS and loss of this potency. Immunology (1973) 1.13
Complement-mediated enhancement of HIV-1 infection of the monoblastoid cell line U937. AIDS (1990) 1.13
Decay-accelerating factor (CD55) protects human immunodeficiency virus type 1 from inactivation by human complement. Eur J Immunol (1995) 1.12
Isolation and biochemical characterization of the iC3b receptor of Candida albicans. Infect Immun (1993) 1.12
Use of monoclonal antibodies against factor H to investigate the role of a membrane-associated protein antigenically related to H in C3b-receptor function. J Immunol (1984) 1.12
Glomerular deposition of mannose-binding lectin in human glomerulonephritis. Nephrol Dial Transplant (1999) 1.12
Activation of human monocytes by both human beta 1H and C3b. Immunology (1982) 1.11
High risk of developing toxoplasmic encephalitis in AIDS patients seropositive to Toxoplasma gondii. Med Microbiol Immunol (1991) 1.11
Uncaria tomentosa (Willd.) DC.--ethnomedicinal use and new pharmacological, toxicological and botanical results. J Ethnopharmacol (1999) 1.11
Detachment of human immunodeficiency virus type 1 from germinal centers by blocking complement receptor type 2. J Virol (2000) 1.11
Listeria monocytogenes cholecystitis. Z Gastroenterol (1989) 1.10
A novel mechanism of alternative pathway complement activation accounts for the deposition of C3 fragments on CR2-expressing homologous cells. J Immunol (1997) 1.10
Factor D in the alternate pathway of complement activation: purification, physicochemical characterization and functional role. Immunochemistry (1974) 1.09
Comparison of two laboratory methods for the determination of serum resistance in Borrelia burgdorferi isolates. Immunobiology (2000) 1.09
In vitro studies on the activity of amphotericin B and lipid-based amphotericin B formulations against Aspergillus conidia and hyphae. Mycoses (2002) 1.08
Complement bridges between cells analysis of a possible cell-cell interaction mechanism. J Exp Med (1977) 1.08
Antibodies in human sera recognizing a recombinant outer membrane protein encoded by the envelope gene of the human endogenous retrovirus K. AIDS Res Hum Retroviruses (1993) 1.08
Barbecued chicken causing a multi-state outbreak of Campylobacter jejuni enteritis. Infection (2003) 1.07
Increased expression of Candida albicans secretory proteinase, a putative virulence factor, in isolates from human immunodeficiency virus-positive patients. J Clin Microbiol (1995) 1.07
Who will get AIDS? Lancet (1986) 1.07
Receptor-binding sites on C3 and C3b. J Immunol (1977) 1.07
Human complement factor H: expression of an additional truncated gene product of 43 kDa in human liver. Eur J Immunol (1987) 1.06
Meningococcal septicaemia in a C6-deficient patient and effects of plasma transfusion on lipopolysaccharide release. Lancet (1992) 1.06
Envelope gene-derived recombinant peptide in the serodiagnosis of human immunodeficiency virus infection. Lancet (1986) 1.06
C3 receptors on lymphoid cells: isolation of active membrane fragments and solubilization of receptor complexes. J Immunol (1975) 1.05
Immune activation and the anaemia associated with chronic inflammatory disorders. Eur J Haematol (1991) 1.05
C3-mediated cytoadherence. Formation of C3 receptor aggregates as prerequisite for cell attachment. J Exp Med (1975) 1.04
Autoantibodies against C1q: view on clinical relevance and pathogenic role. Clin Exp Immunol (1999) 1.03
Properties of a low molecular weight complement component C6 found in human subjects with subtotal C6 deficiency. Immunology (1992) 1.03
Properdin, a positive regulator of complement activation, is expressed in human T cell lines and peripheral blood T cells. J Immunol (1993) 1.02
In vivo activation of CD4+ cells in AIDS. Science (1987) 1.02
Borreliacidal activity of early Lyme disease sera against complement-resistant Borrelia afzelii FEM1 wild-type and an OspC-lacking FEM1 variant. J Med Microbiol (2000) 1.02
Serological crossreaction of human herpesvirus-6 with cytomegalovirus. Lancet (1988) 1.01
Serum HIV-1 RNA levels compared to soluble markers of immune activation to predict disease progression in HIV-1-infected individuals. Int Arch Allergy Immunol (1998) 1.01
Identification and characterization of complement C3 receptors on human astrocytes. J Immunol (1996) 1.01
Complement receptors: another port of entry for HIV. Lancet (1989) 1.00
Human polymorphonuclear leukocytes store large amounts of terminal complement components C7 and C6, which may be released on stimulation. J Immunol (1995) 1.00
Incidence of fecal carriage of Listeria monocytogenes in three healthy volunteers: a one-year prospective stool survey. Eur J Clin Microbiol Infect Dis (2003) 1.00
Characterization of C3dg binding to a recess formed between short consensus repeats 1 and 2 of complement receptor type 2 (CR2; CD21). J Immunol (1998) 0.99
[Serum neopterin determination for the additional safeguarding of blood transfusions. Our experiences with 76,587 blood donors]. Dtsch Med Wochenschr (1989) 0.99
Prevalence and clinical manifestations of Shiga toxin-producing Escherichia coli infections in Austrian children. Eur J Clin Microbiol Infect Dis (1996) 0.98
The envelope glycoprotein of HIV-1 gp120 and human complement protein C1q bind to the same peptides derived from three different regions of gp41, the transmembrane glycoprotein of HIV-1, and share antigenic homology. Eur J Immunol (1994) 0.98
Human complement factor H: an additional gene product of 43 kDa isolated from human plasma shows cofactor activity for the cleavage of the third component of complement. Eur J Immunol (1989) 0.98
beta 1H stimulates mouse-spleen B lymphocytes as demonstrated by increased thymidine incorporation and formation of B cell blasts. Immunobiology (1981) 0.97
HIV-Protease inhibitors reduce cell adherence of Candida albicans strains by inhibition of yeast secreted aspartic proteases. J Invest Dermatol (1999) 0.96
Molecular bases of combined subtotal deficiencies of C6 and C7: their effects in combination with other C6 and C7 deficiencies. J Immunol (1996) 0.96
Individual epitopes of an 85,000 MW membrane adherence molecule are variably expressed on cells of different lineage. Immunology (1988) 0.96
HIV and HIV-infected cells differentially activate the human complement system independent of antibody. Immunol Lett (1989) 0.96
Identification and characterization of a novel membrane activation antigen with wide cellular distribution. Eur J Immunol (1988) 0.96